非侵入性产前检测市场－全球产业规模、份额、趋势、机会和预测，按产品类型、按检测类型、按方法、按应用、按最终用户、按地区和竞争进行细分，2020 年至 2030 年

2024 年全球非侵入性产前检测 (NIPT) 市值为 50.3 亿美元，预计到 2030 年将达到 77.4 亿美元，预测期内复合年增长率为 7.42%。这种增长是由人们对遗传疾病认识的提高以及对更安全、非侵入性产前筛检替代方案的需求所推动的。随着全球孕妇年龄的不断增长，染色体异常的风险也在不断增加，这促使人们更广泛地采用 NIPT 作为首选筛检方法。该技术仅需从母亲体内提取简单的血液样本即可提供准确的结果，从而消除了羊膜穿刺术等侵入性手术带来的风险。政府对早期诊断措施的支持、私人医疗保健服务的进步以及快速获得结果的便利性进一步促进了市场的发展。此外，基于人工智慧的分析和多重检测开发等创新正在拓宽 NIPT 的范围和精度，而消费者对家庭检测解决方案的需求正在重塑交付模式，使其更加以患者为中心。

关键市场驱动因素

母亲年龄增长与染色体异常相关风险

主要市场挑战

NIPT的局限性

主要市场趋势

直接面向消费者的测试可用性

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球无创产前检测（NIPT）市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品类型（耗材、仪器）
  • 依测试类型（Materni 21、Harmony、Panaroma、Verifi、NIFTY、其他）
  • 依方法（超音波检测、生化筛检检测、母体血浆游离DNA检测、母体血液中的胎儿细胞检测、其他）
  • 依应用（三体症候群、微缺失症候群、其他）
  • 按最终使用者（诊断实验室、医院、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美非侵入性产前检测（NIPT）市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲非侵入性产前检测（NIPT）市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太地区非侵入性产前检测（NIPT）市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲无创产前检测（NIPT）市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲非侵入性产前检测（NIPT）市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球非侵入性产前检测（NIPT）市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F.Hoffman La Roche Ltd.
• Perkin Elmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodex GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Non-invasive Prenatal Testing (NIPT) Market was valued at USD 5.03 billion in 2024 and is projected to reach USD 7.74 billion by 2030, growing at a CAGR of 7.42% during the forecast period. This growth is driven by increased awareness of genetic disorders and the demand for safer, non-invasive prenatal screening alternatives. As maternal age continues to rise globally, so does the risk of chromosomal abnormalities, prompting wider adoption of NIPT as a preferred screening option. The technology offers accurate results using a simple blood sample from the mother, eliminating risks associated with invasive procedures like amniocentesis. Government support for early diagnostic initiatives, advancements in private healthcare access, and the convenience of rapid results further bolster the market. Additionally, innovations such as AI-based analysis and multiplex assay development are broadening the scope and precision of NIPT, while consumer demand for home-based testing solutions is reshaping delivery models to become more patient-centric.

Key Market Drivers

Rising Maternal Age and Associated Risk of Chromosomal Abnormalities

The trend of delayed motherhood, particularly across Europe, is fueling demand for NIPT. As women increasingly postpone childbirth for career or financial reasons, the average maternal age continues to climb-reaching 30.9 years in England and Wales in 2023, according to the ONS. This age shift is associated with heightened risk for chromosomal anomalies like Down syndrome, Edwards syndrome, and Patau syndrome. NIPT has become the preferred screening method due to its high accuracy, non-invasive nature, and safety for both mother and fetus. The growing maternal population over the age of 35 is particularly inclined to choose NIPT over invasive diagnostic tests. The incorporation of NIPT into public healthcare systems such as the NHS has further increased access, supporting its widespread adoption as part of routine prenatal care.

Key Market Challenges

Limitations of NIPT

Despite its advantages, NIPT faces certain limitations that hinder universal adoption. The possibility of false-positive or false-negative results may lead to unnecessary follow-up procedures or missed diagnoses, undermining patient confidence. Since NIPT is a screening-not diagnostic-tool, positive results must be confirmed through invasive testing methods like amniocentesis or CVS, which may deter some from pursuing initial screening. Additionally, NIPT is largely focused on detecting chromosomal abnormalities and may not identify rare or functional genetic disorders, leaving gaps in comprehensive fetal health assessment. Cost also remains a concern, particularly for patients without insurance coverage or in regions where testing is not publicly funded. The lower sensitivity of NIPT for rare conditions and de novo mutations presents further challenges for families seeking exhaustive genetic insights.

Key Market Trends

Availability of Direct-to-Consumer Tests

The emergence of direct-to-consumer (DTC) NIPT is reshaping the market by expanding accessibility and convenience. These at-home testing options enable individuals to initiate genetic screening without visiting a healthcare provider, promoting early decision-making and broader adoption. DTC models align with the broader movement toward personalized and proactive healthcare, offering users greater control over prenatal care choices. They are especially beneficial for individuals in remote or underserved regions who face barriers to in-clinic services. While concerns over result interpretation and medical oversight remain, the convenience and consumer empowerment offered by DTC NIPT options are expected to drive future demand and innovation within the market.

Key Market Players

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F. Hoffman-La Roche Ltd.
• PerkinElmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodexx GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

• Consumables
• Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

• Materni 21
• Harmony
• Panaroma
• Verifi
• NIFTY
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Method:

• Ultrasound Detection
• Biochemical Screening Testing
• Cell-Free DNA Maternal Plasma Tests
• Fetal Cells in Maternal Blood Tests
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Application:

• Trisomy
• Microdeletion Syndrome
• Others

Non-invasive Prenatal Testing (NIPT) Market, By End User:

• Diagnostic Laboratories
• Hospitals
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Consumables, Instruments)
  • 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
  • 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
  • 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
  • 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Test Type
  • 6.2.3. By Method
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Method
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Method
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Method
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Test Type
  • 7.2.3. By Method
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Method
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Method
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Method
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. France Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Method
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Method
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Test Type
  • 8.2.3. By Method
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Method
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Method
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Method
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Method
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Method
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Test Type
  • 9.2.3. By Method
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Method
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Method
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Method
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Test Type
  • 10.2.3. By Method
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Method
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Method
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Method
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Non-invasive Prenatal Testing (NIPT) Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. YOURGENE HEALTH Plc
• 15.2. Illumina, Inc.
• 15.3. Natera, Inc.
• 15.4. F.Hoffman La Roche Ltd.
• 15.5. Perkin Elmer Inc.
• 15.6. Laboratory Corporation of America Holdings
• 15.7. Eurofins LifeCodex GmbH
• 15.8. Progenity, Inc.
• 15.9. Genesis Genetics
• 15.10. Quest Diagnostics Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer